Rexahn Pharmaceuticals CEO Peter Suzdak's 2018 pay jumps 62% to $1.3M
Rexahn Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 29, 2019
Rexahn Pharmaceuticals reported fiscal year 2018 executive compensation information on April 29, 2019.
In 2018, four executives at Rexahn Pharmaceuticals received on average a compensation package of $958K, a 64% increase compared to previous year.
Average pay of disclosed executives at Rexahn Pharmaceuticals
Peter D. Suzdak, Chief Executive Officer, received $1.3M in total, which increased by 62% compared to 2017.
Douglas J. Swirsky, Chief Executive Officer, received a compensation package of $1.2M. 59% of the compensation package, or $704K, was in option awards.
Ely Benaim, Chief Medical Officer, earned $851K in 2018, a 37% increase compared to previous year.
Lisa Nolan, Secretary, received $494K in 2018, which increases by 5% compared to 2017.
Related executives
You may also like
Source: SEC filing on April 29, 2019.